Dudediligence.

Cytokinetics, Incorporated

CYTKNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$463,000Sep ’24$16.9MDec ’24$1.6MMar ’25$66.8MJun ’25$1.9MSep ’25$17.8MDec ’25$19.4MMar ’26$28.6MJun ’26
Net income, by quarter
−$160.5MSep ’24−$150.0MDec ’24−$161.4MMar ’25−$134.4MJun ’25−$306.2MSep ’25−$183.0MDec ’25−$206.0MMar ’26−$198.8MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$70.4M$94.6M$7.5M$18.5M$88.0M
Operating income−$186.3M−$324.2M−$496.2M−$536.2M−$612.3M
Net income−$215.3M−$389.0M−$526.2M−$589.5M−$785.0M
Operating cash flow−$142.5M−$299.5M−$414.3M−$395.9M−$510.0M
Free cash flow−$191.4M−$310.9M−$415.7M−$399.8M−$534.8M
Cash$112.7M$65.6M$113.0M$94.9M$122.5M
Debt$47.4M$64.8M$68.5M$104.7M$287.6M
Shares outstanding84.8M94.8M101.6M118.2M122.9M